NASDAQ$HSIC

Henry Schein Inc · Q4 2024 earnings

Q4 2024 earnings · · Before market open · Investor relations

Briefing

Henry Schein Inc. reported stable Q4 2024 earnings with a 5.8% increase in revenue and strong non-GAAP EPS growth.

Henry Schein Inc. delivered a solid fourth quarter, achieving a 5.8% increase in total net sales. GAAP net income surged to $94 million, and non-GAAP net income increased to $149 million. Adjusted EBITDA also rose significantly to $270 million, reflecting strong operational performance. The company’s restructuring efforts contributed to cost efficiencies, supporting future growth.

  • Total net sales increased 5.8% year-over-year to $3.19 billion.
  • GAAP net income reached $94 million, with non-GAAP net income at $149 million.
  • Adjusted EBITDA improved to $270 million from $172 million in Q4 2023.
  • Strong sales growth across Global Dental and Specialty Products segments.

Headline financials

Total Revenue

$3.19B

Previous: $3.02B+5.8%
EPS (adj)

$1.19

Previous: $0.66+80.3%
Adjusted EBITDA

$270M

No prior period
Capital Expenditures

-$36M

Previous: -$79M+54.4%
Net Income

$94M

Previous: $17M+452.9%
Operating Income

$155M

Previous: $39M+297.4%
Gross Profit

$993M

Previous: $867M+14.5%

Revenue & EPS history

Henry Schein · Revenue · Quarterly

$3.19B

Q4 2024+5.8%vs Q4 2023
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Revenue by segment

Henry Schein · $3B total across 2 segments · Q3 2023

  • Global Dental
    $1.9B+5.6%
  • Global Medical
    $1.1B+0.0%

Forward guidance

Henry Schein expects moderate growth in 2025, with total sales projected to increase by 2-4% and non-GAAP EPS ranging between $4.80 and $4.94.

Tailwinds

  • Total sales growth forecasted at 2-4% for FY 2025.
  • Non-GAAP diluted EPS expected between $4.80 and $4.94.
  • Adjusted EBITDA projected to grow in mid-single digits.
  • Continued benefits from restructuring and operational efficiencies.
  • Strong outlook for specialty products and technology solutions.

Headwinds

  • Foreign currency fluctuations may impact revenue growth.
  • Macroeconomic uncertainty could influence demand.
  • Ongoing restructuring costs may weigh on short-term profitability.
  • Potential cybersecurity risks remain a concern.
  • Competitive pressures in the medical and dental markets.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

-0.4%

Avg return

Earnings day

-0.5%

Avg return

5 days after

-0.6%

Avg return

30 days after

45%

31 / 69 earnings

Positive

+11.1%

Q4 2021

Best reaction

-8.5%

Q3 2017

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+3.3%-1.6%+4.6%
Q4 2025+5.8%+2.3%-8.5%
Q3 2025+10.9%+11.2%+13.5%
Q1 2025+2.0%+5.1%+7.8%
Q4 2024-2.3%-7.0%-10.6%
Q3 2024-3.2%-6.0%+0.2%
Q2 2024-5.4%-0.9%+0.4%
Q1 2024+6.2%+7.0%+0.1%
Q4 2023-5.1%-4.6%-6.3%
Q3 2023+7.5%+7.3%+15.5%
Q2 2023-2.8%-1.8%-5.1%
Q1 2023-4.5%-4.2%-6.1%
Q4 2022-6.2%-7.5%-12.8%
Q3 2022+1.8%+6.2%+21.2%
Q2 2022-4.9%-3.8%-7.3%
Q1 2022+7.4%+6.6%+5.6%
Q4 2021+11.1%+10.1%+14.5%
Q3 2021+3.0%+4.5%-6.7%
Q2 2021-4.8%-5.2%-2.3%
Q1 2021+6.6%+8.9%+5.3%
Q4 2020-8.5%-6.5%-5.3%
Q3 2020-5.0%-3.0%+4.6%
Q2 2020-5.3%-4.4%-6.9%
Q1 2020+0.4%+2.9%+20.6%
Q4 2019-8.4%-14.4%-38.9%
Q3 2019+4.4%+4.8%+5.2%
Q2 2019-3.2%-2.3%-4.2%
Q1 2019+8.6%+8.9%+8.6%
Q4 2018-5.0%-5.2%-5.2%
Q3 2018+3.1%+0.8%+3.3%
Q2 2018-0.5%-3.6%+0.5%
Q1 2018-6.1%-4.4%-6.7%
Q4 2017-1.2%-2.1%-5.2%
Q3 2017-8.5%-13.6%-13.0%
Q2 2017-7.7%-7.2%-4.9%
Q1 2017+0.6%+0.3%+5.2%
Q4 2016+2.7%+3.2%+2.0%
Q3 2016+4.6%+6.2%+1.7%
Q2 2016-7.1%-8.4%-8.6%
Q1 2016-2.5%
Q4 2015+7.0%
Q3 2015+1.1%
Q2 2015-1.9%
Q1 2015-0.4%
Q4 2014+0.9%
Q3 2014+5.4%
Q2 2014-1.8%
Q1 2014-1.7%
Q4 2013+0.1%
Q3 2013-2.6%
Q2 2013-0.3%
Q1 2013+2.1%
Q4 2012-2.2%
Q3 2012-0.6%
Q2 2012+1.8%
Q1 2012+2.4%
Q4 2011+3.4%
Q3 2011-6.4%
Q2 2011-2.3%
Q1 2010-2.0%
Q1 2011+0.5%
Q4 2010-3.9%
Q1 2009-3.9%
Q4 2008-3.9%
Q3 2009-4.1%
Q3 2010-4.1%
Q2 2010+2.1%
Q4 2009+2.1%
Q2 2009+2.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro